List of Excipients in Branded Drug KOVANAZE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
St Renatus	KOVANAZE	tetracaine hydrochloride and oxymetazoline hydrochloride	69803-100	ANHYDROUS CITRIC ACID	2030-04-02
St Renatus	KOVANAZE	tetracaine hydrochloride and oxymetazoline hydrochloride	69803-100	BENZYL ALCOHOL	2030-04-02
St Renatus	KOVANAZE	tetracaine hydrochloride and oxymetazoline hydrochloride	69803-100	HYDROCHLORIC ACID	2030-04-02

Kovanaze Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Kovanaze is an investigational intranasal dental anesthetic combining tetracaine hydrochloride, a local anesthetic, with oxymetazoline hydrochloride, a nasal vasoconstrictor. Its commercial value depends on solving three formulation problems: rapid nasal absorption, reproducible dosing, and tolerability during repeated intranasal administration. The product is not an FDA-approved drug, so it has no active Orange Book listing, approved exclusivity period, or approved generic pathway. Its strongest commercial opportunity is a differentiated, needle-free dental anesthesia product supported by formulation, device, and method-of-use protection.

What is Kovanaze and how does its formulation work?

Kovanaze, also identified in development materials as ST-001, is designed to deliver local anesthesia through the nasal mucosa for dental procedures involving maxillary teeth. Tetracaine hydrochloride provides local anesthetic activity. Oxymetazoline hydrochloride constricts nasal blood vessels, potentially improving local residence time and reducing systemic absorption.

Public clinical materials describe Kovanaze as an aqueous nasal spray containing tetracaine hydrochloride and oxymetazoline hydrochloride. Reported development formulations have used approximately 3% tetracaine hydrochloride and 0.05% oxymetazoline hydrochloride, although the final commercial composition would depend on the regulatory formulation and device combination used for any future application [1,2].

The formulation has four technical objectives:

1. Dissolve both active ingredients in a stable aqueous system.
2. Deliver a consistent spray volume to the nasal mucosa.
3. Maintain sufficient nasal residence time without excessive irritation.
4. Produce clinically meaningful anesthesia while limiting swallowing, dripping, sneezing, and systemic exposure.

Kovanaze’s formulation is therefore more complex than a conventional nasal decongestant. The product must coordinate anesthetic potency, vasoconstriction, nasal tolerability, spray performance, and dental procedure timing.

What excipients are relevant to Kovanaze?

The highest-value excipient choices are buffers, tonicity agents, viscosity modifiers, wetting agents, preservatives, and chemical stabilizers. Each excipient affects both clinical performance and intellectual-property differentiation.

Excipient function	Candidate materials	Commercial relevance
pH control	Citrate, phosphate, acetate buffers	Controls tetracaine stability, solubility, irritation, and preservative performance
Tonicity adjustment	Sodium chloride, dextrose, mannitol	Reduces nasal discomfort and improves tolerability
Viscosity enhancement	Hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, carbomer	Increases mucosal residence time but can impair sprayability
Wetting and solubilization	Polysorbates, poloxamers, cyclodextrins	May improve wetting and formulation uniformity
Preservation	Benzalkonium chloride, phenoxyethanol, alternative antimicrobial systems	Supports multidose packaging but can create chronic-use tolerability concerns
Antioxidant or chelator	Sodium metabisulfite, EDTA	May improve chemical stability where degradation pathways justify use
Osmotic adjustment	Sodium chloride or equivalent	Helps align formulation osmolality with nasal tissue
Device compatibility	Low-extractable surfactants and container-contact materials	Limits adsorption, leachables, valve failures, and dose drift

The preferred formulation should minimize excipient count. A simple buffered aqueous formulation is easier to manufacture, characterize, scale, and defend before the FDA than a heavily modified mucoadhesive system.

What excipient strategy best supports Kovanaze commercialization?

A three-tier formulation strategy is appropriate.

Tier 1: Simple buffered aqueous spray

The primary development candidate should use tetracaine hydrochloride and oxymetazoline hydrochloride in a mildly acidic, isotonic or near-isotonic aqueous vehicle. A low excipient burden reduces toxicology requirements and simplifies comparability testing.

The development program should prioritize:

• Buffer capacity sufficient to resist pH drift.
• Tonicity close to nasal physiological conditions.
• Minimal surfactant use.
• Preservative compatibility with the spray pump.
• Low viscosity that preserves plume geometry and dose uniformity.
• Protection against microbial contamination in a multidose package.

This approach has the clearest regulatory path and the lowest manufacturing cost.

Tier 2: Mild mucoadhesion

A low-level viscosity modifier could improve nasal residence time and reduce post-dose runoff. Hydroxypropyl cellulose, hydroxypropyl methylcellulose, or povidone may be preferable to a highly crosslinked polymer because the spray must remain compatible with a metered-dose pump.

Mucoadhesion creates a tradeoff. Higher viscosity may improve retention but can produce:

• Larger droplets.
• Reduced plume coverage.
• Inconsistent emitted dose.
• Greater sensation of nasal blockage.
• More variable delivery across patients.
• Increased cleaning or clogging risk.

The formulation should target the lowest viscosity that produces a measurable residence-time benefit.

Tier 3: Advanced permeation or retention system

Cyclodextrins, surfactants, lipid-based systems, or specialized mucoadhesive polymers could increase mucosal uptake. These systems should be reserved for a reformulation with a clear clinical objective, such as reducing the number of sprays or improving efficacy in patients with larger nasal anatomy.

An advanced system could generate composition-of-matter and formulation patents, but it would also increase development cost, excipient qualification requirements, local tolerability risk, and manufacturing complexity.

What formulation patents could protect Kovanaze?

Kovanaze’s defensible patent position can be divided into five categories:

1. Composition patents covering the combination of tetracaine or another local anesthetic with oxymetazoline.
2. Formulation patents covering concentration ranges, pH, osmolality, viscosity, preservatives, or stabilizers.
3. Device patents covering the metered nasal spray, actuator, nozzle, or dose-control system.
4. Method-of-use patents covering dental anesthesia, specific tooth regions, dosing intervals, or needle-free administration.
5. Manufacturing patents covering sterile or nonsterile filling, mixing order, filtration, and container closure.

A reformulation strategy should not depend solely on a broad combination claim. Such claims may face validity challenges based on prior-art nasal anesthetics, vasoconstrictors, and dental local-anesthetic techniques.

The strongest later-filed patent opportunities would likely involve a narrow combination of:

• Defined active-ingredient ratios.
• A specified pH and osmolality window.
• A viscosity range linked to spray performance.
• A validated metered dose.
• A specific nasal deposition profile.
• A clinical result, such as adequate anesthesia after a defined number of sprays.

A formulation patent is more commercially valuable when the claimed excipient range is tied to measurable performance. Claims limited to routine choices of buffer or sodium chloride are more vulnerable to obviousness attacks.

What is the Orange Book status of Kovanaze?

Kovanaze does not have an FDA-approved NDA and therefore does not have an active Orange Book listing. The product has no approved small-molecule exclusivity period, no listed patents under section 505(b)(1), and no established generic reference product [3].

Regulatory item	Kovanaze status
FDA approval	Not approved in the public FDA record through 2024
Reference-listed drug	None
Orange Book patents	None listed
New chemical entity exclusivity	None awarded
Paragraph IV litigation	No Orange Book-based litigation pathway
Biosimilar exposure	Not applicable
505(b)(2) competition	Possible if a future product is approved through that pathway
Generic substitution	Not available without an approved reference product

The absence of Orange Book protection does not eliminate patent risk. A future sponsor could rely on patent claims outside the Orange Book, including formulation, device, manufacturing, or method-of-use claims.

When does Kovanaze lose exclusivity?

Kovanaze has no current FDA exclusivity expiration date because it has not received FDA approval. If approved as a new drug, exclusivity would depend on the regulatory classification of the active ingredients and the approval pathway.

Potential outcomes include:

• Five years of new chemical entity exclusivity if FDA determines that the approved product contains a qualifying new active moiety.
• Three years of exclusivity for a new clinical investigation supporting approval of a previously known active ingredient.
• Patent protection based on any valid and enforceable formulation, device, or method claims.
• Pediatric exclusivity if the sponsor completes qualifying studies under a written FDA request.

Because tetracaine and oxymetazoline are established active ingredients, five-year NCE treatment is not assured. The combination, route, or dosage form alone would not automatically create NCE status.

What FDA regulatory issues affect Kovanaze?

The FDA accepted a Kovanaze new drug application for review, but the agency issued a Complete Response Letter after review. Public reports identified efficacy concerns, including performance in patients with higher body weight and the need for additional evidence supporting reliable anesthesia across the intended population [4].

The main regulatory risks are:

• Inconsistent anesthesia in larger patients.
• Variable nasal anatomy and mucosal absorption.
• Insufficient efficacy after the initial dose.
• Need for repeat administration.
• Nasal irritation, congestion, epistaxis, or burning.
• Systemic tetracaine exposure.
• Cardiovascular effects from oxymetazoline.
• Dose variability from pump performance.
• Product quality changes during storage.
• Clinical relevance of excipient changes.

A reformulation intended to improve efficacy would likely require bridging studies. Changes in viscosity, spray pattern, droplet size, pH, preservative, or device could alter nasal deposition enough to trigger new clinical requirements.

What manufacturing and IP barriers exist?

Kovanaze has several manufacturing barriers that create opportunities for differentiated suppliers.

Active-ingredient compatibility

Tetracaine hydrochloride and oxymetazoline hydrochloride must remain chemically stable in the same vehicle. The sponsor must control pH, temperature, light exposure, oxygen exposure, and contact with packaging materials.

Spray-device performance

The commercial dose is defined by the combination of formulation and pump. Critical quality attributes include:

• Delivered volume.
• Dose uniformity.
• Priming and re-priming behavior.
• Droplet-size distribution.
• Spray-pattern geometry.
• Container-closure integrity.
• Performance near the end of container life.

Device patents can create barriers even where the liquid formulation is not strongly protected.

Microbiological control

A multidose nasal spray requires a robust microbial-control strategy. A preservative-free design would require a specialized container or unit-dose presentation. A preserved formulation would need nasal-tolerability data and preservative-effectiveness testing.

Scale-up

Mixing order, filtration, hold time, filling temperature, and pump assembly can alter active concentration and spray performance. A manufacturing patent could cover process controls that maintain uniformity without aseptic processing.

Which commercial opportunities exist for Kovanaze excipients?

The commercial opportunity is broader than supplying commodity excipients.

Premium nasal-delivery platform

A supplier could offer a validated nasal-delivery platform combining a low-viscosity mucoadhesive polymer, compatible preservative system, and optimized spray device. The value proposition would be reduced development time and stronger performance data.

Preservative-free packaging

A unit-dose or multidose preservative-free system could differentiate Kovanaze for dental offices concerned about nasal irritation. The tradeoff is higher packaging cost and more complex clinic handling.

Low-irritation formulation

An excipient system optimized for pH, osmolality, and reduced surfactant exposure could improve acceptance among patients who resist nasal administration.

Reformulation for fewer sprays

If clinical efficacy is limited by inadequate deposition or absorption, a more concentrated or more retentive formulation could support one-spray administration. This opportunity would require new dose-ranging, local-tolerability, and device studies.

Dental-office packaging

Commercial packaging could use single-patient, single-procedure units with clear dose counters and tamper evidence. Such packaging may reduce contamination risk and support premium pricing even if the underlying formulation is not novel.

How does Kovanaze compare with injectable dental anesthetics?

Attribute	Kovanaze	Injectable lidocaine or articaine
Administration	Intranasal spray	Needle injection
Main advantage	Needle-free delivery	High and predictable local efficacy
Primary limitation	Variable nasal deposition and anesthetic response	Pain, needle anxiety, injection skill
Procedure fit	Selected maxillary dental procedures	Broad dental use
Device dependence	High	Moderate
Excipient importance	High because absorption depends on nasal formulation	Lower for routine injectable solutions
Commercial positioning	Patient convenience and needle avoidance	Established standard of care
Generic pressure	No approved reference product currently	Strong generic competition

Kovanaze is unlikely to replace injectable anesthetics across all dental procedures. Its best position is as a needle-free option for selected procedures and patients, including children, needle-phobic patients, and dental settings seeking faster patient throughput.

Which companies could challenge Kovanaze?

The principal competitive threats are not biosimilars. Kovanaze is a small-molecule combination, so biosimilar competition does not apply.

Potential competitors include:

• Generic manufacturers developing intranasal tetracaine or oxymetazoline combinations.
• Dental-anesthetic companies commercializing alternative needle-free systems.
• Device companies offering intranasal or trans-mucosal delivery platforms.
• Sponsors developing topical anesthetic gels, patches, or iontophoretic systems.
• Manufacturers using 505(b)(2) pathways to rely partly on published safety data for known active ingredients.

A future competitor could avoid Kovanaze claims by changing the anesthetic, concentration ratio, polymer system, spray device, or treatment method.

What generic launch risks exist?

A generic or follow-on launch would face several barriers:

1. No approved reference product currently establishes an ANDA pathway.
2. Formulation and device sameness may be difficult to demonstrate.
3. The nasal spray may require comparative performance testing.
4. Method-of-use claims could complicate labeling.
5. A future sponsor may pursue 505(b)(2) approval rather than an ANDA.
6. Device differences could require clinical bridging.
7. A narrow dental indication may limit commercial scale.

The most realistic early competition would be another branded or 505(b)(2) product, not a conventional tablet-style generic launch.

What is the revenue opportunity for Kovanaze?

Kovanaze’s revenue opportunity depends on penetration into U.S. dental procedures rather than broad pharmaceutical prescribing. Commercial success would require a clear economic benefit for dentists, such as reduced procedure time, fewer injections, improved patient acceptance, or differentiated reimbursement.

The strongest launch segments are:

• Pediatric dentistry.
• Patients with needle phobia.
• Dental practices offering minimally invasive procedures.
• Procedures involving selected maxillary teeth.
• Clinics seeking premium patient-experience products.
• International markets with less dependence on U.S. dental reimbursement.

Pricing power would depend on whether the product is treated as a convenience product or as a replacement for injectable anesthetic. A high price without documented workflow savings would increase adoption risk.

Key Takeaways

• Kovanaze combines tetracaine hydrochloride and oxymetazoline hydrochloride in an investigational intranasal dental-anesthetic product.
• The most important excipient variables are pH, tonicity, viscosity, preservative selection, and spray-device compatibility.
• A simple buffered aqueous formulation offers the lowest regulatory and manufacturing risk.
• Mild mucoadhesion could improve residence time, but excessive viscosity may impair spray performance.
• Kovanaze has no FDA approval, Orange Book listing, approved exclusivity period, or established generic reference product.
• Its strongest patent opportunities are formulation-device combinations tied to dose uniformity, nasal deposition, and clinical performance.
• Biosimilar risk is not applicable because Kovanaze is a small-molecule product.
• The principal commercial position is needle-free anesthesia for selected dental procedures, not universal replacement of injectable anesthetics.
• A future competitor is more likely to use a 505(b)(2) or new NDA strategy than a conventional ANDA pathway.

FAQs About Kovanaze Excipient and Commercial Strategy

Can benzalkonium chloride be used in Kovanaze?

It could support multidose preservation, but chronic nasal exposure and local tolerability would require careful justification. A preservative-free container system may provide a stronger differentiation strategy.

Would a mucoadhesive polymer improve Kovanaze efficacy?

A low-viscosity polymer may improve nasal residence time and reduce runoff. Higher viscosity can reduce spray uniformity and create nasal discomfort, so the benefit must be demonstrated through deposition and clinical testing.

Is Kovanaze eligible for biosimilar competition?

No. Kovanaze is a small-molecule drug candidate, not a biologic. Competition would arise through generic, 505(b)(2), reformulated, or alternative-device products.

Could Kovanaze receive five years of new chemical entity exclusivity?

That outcome is not automatic. FDA would determine whether the approved active moiety qualifies for NCE exclusivity, and the established history of tetracaine and oxymetazoline could limit that possibility.

What is the most valuable patent claim for a Kovanaze follow-on product?

A claim linking a defined excipient system and spray-device configuration to improved dose uniformity, nasal deposition, or dental-anesthesia efficacy would generally be more commercially useful than a broad claim covering routine buffers or tonicity agents.

References

1. ClinicalTrials.gov. (2016). Nasal anesthesia for dental procedures: SONATA clinical study, NCT02623478. U.S. National Library of Medicine.

2. St. Renatus, LLC. (2016). Kovanaze: Intranasal anesthetic development materials. St. Renatus.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2017). Briefing information for the Anesthetic and Analgesic Drug Products Advisory Committee: Kovanaze nasal spray. U.S. Department of Health and Human Services.